罗格列酮联合辛伐他汀治疗混合性高脂血症的临床分析.docVIP

罗格列酮联合辛伐他汀治疗混合性高脂血症的临床分析 　　[摘要] 目的 观察罗格列酮联合辛伐他汀治疗混合性高脂血症的临床效果与安全性。 方法 将158例混合性高脂血症患者随机分为两组，对照组79例患者给予辛伐他汀治疗，观察组79例患者则在对照组的基础上加用罗格列酮治疗，比较两组的临床疗效。 结果 观察组总有效率为93.67%，对照组为81.01%（P 0.05）；观察组的总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）与3项达标均优于对照组（P 0.05），两组患者的TC、LDL-C、TG、高密度脂蛋白胆固醇（HDL-C）与治疗前比较P 0.05，治疗后观察组TC、LDL-C、TG、HDL-C均优于对照组（P 0.05）。 结论 罗格列酮联合辛伐他汀治疗混合性高脂血症疗效确切，具有良好的耐受性。 　　[关键词] 混合性高脂血症；罗格列酮；辛伐他汀 　　[中图分类号] R54 [文献标识码] A [文章编号] 1674-4721（2013）06（c）-0048-03 　　Clinical analysis of the rosiglitazone combined with simvastatin in treatment for mixed hyperlipidemia 　　SONG Daili HUANG Haifeng 　　Department of Cardiology，the Third Peoples Hospital of Nanhai District in Foshan City，Guangdong Province，Foshan 528244，China 　　[Abstract] Objective To discuss the clinical safety and efficacy of the rosiglitazone combined with simvastatin in treatment for mixed hyperlipidemia. Methods 158 cases of patients with mixed hyperlipidemia were randomly divided into two groups according to figures，79 patients in the control group were treated with simvastatin，79 patients in were treated by the rosiglitazone on the basis of the control group，and then compared their effects. Results The total effective rate of the observation group was 93.67%，and the control group was 81.01% （P 0.05），the TC，TG，LDL-C and 3 standards of the observation group were all better than the control group （P 0.05），the TC，LDL-C，TG，and HDL-C of two groups were compared with before treatment P 0.05，after treatment，TC，LDL-C，TG，and HDL-C of the observation group were better than the control group （P 0.05）. Conclusion Rosiglitazone combined with simvastatin treatment of mixed hyperlipidemia efficacy with good tolerability. 　　[Key words] Mixed hyperlipidemia；Rosiglitazone；Simvastatin 　　随着人们生活水平的逐渐提高，高脂血症的发病率居高不下。高脂血症是脂代谢紊乱的标志，是心脏病、动脉粥样硬化、脑卒中和脂肪肝的主要危害因素之一[1]。混合性高脂血症患者日益增加，血脂紊乱是冠心病患者威胁最大的因素，而血脂异常是动脉粥样硬化密切相关的危险因素之一，尤为重要的则是总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C），而至关重要的还有三酰甘油（TG）和高密度脂蛋白胆固醇（HDL-C），所以国际上有专家学者认为除TC和 LDL-C达标外，TG和 HDL-C也要达标才是